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1553Stent Thrombosis in Drug-Eluting or
Bare-Metal Stents in Patients Receiving
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froOBJECTIVES This study sought to compare rates of stent thrombosis and major adverse cardiac and cerebrovascular
events (MACCE) (composite of death, myocardial infarction, or stroke) after coronary stenting with drug-eluting stents
(DES) versus bare-metal stents (BMS) in patients who participated in the DAPT (Dual Antiplatelet Therapy) study, an
international multicenter randomized trial comparing 30 versus 12 months of dual antiplatelet therapy in subjects
undergoing coronary stenting with either DES or BMS.
BACKGROUND Despite antirestenotic efﬁcacy of coronary DES compared with BMS, the relative risk of stent throm-
bosis and adverse cardiovascular events is unclear. Many clinicians perceive BMS to be associated with fewer adverse
ischemic events and to require shorter-duration dual antiplatelet therapy than DES.
METHODS Prospective propensity-matched analysis of subjects enrolled into a randomized trial of dual antiplatelet
therapy duration was performed. DES- and BMS-treated subjects were propensity-score matched in a many-to-one
fashion. The study design was observational for all subjects 0 to 12 months following stenting. A subset of eligible
subjects without major ischemic or bleeding events were randomized at 12 months to continued thienopyridine versus
placebo; all subjects were followed through 33 months.
RESULTS Among 10,026 propensity-matched subjects, DES-treated subjects (n ¼ 8,308) had a lower rate of stent
thrombosis through 33 months compared with BMS-treated subjects (n ¼ 1,718, 1.7% vs. 2.6%; weighted risk
difference 1.1%, p ¼ 0.01) and a noninferior rate of MACCE (11.4% vs. 13.2%, respectively, weighted risk
difference 1.8%, p ¼ 0.053, noninferiority p < 0.001).
CONCLUSIONS DES-treated subjects have long-term rates of stent thrombosis that are lower than BMS-treated subjects.
(The Dual Antiplatelet Therapy Study [DAPT study]; NCT00977938) (J Am Coll Cardiol Intv 2015;8:1552–62)
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ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndromes
BMS = bare-metal stent(s)
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
MACCE = major adverse
cardiovascular and
cerebrovascular events
PCI = percutaneous coronary
intervention
PES = paclitaxel-eluting
stent(s)
RD = risk difference
STEMI = ST-segment elevation
myocardial infarction
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1554A lthough drug-eluting stents (DES)have reduced restenosis when com-pared with bare-metal stents (BMS)
for percutaneous coronary intervention
(PCI), the relative hazard for stent throm-
bosis, a potentially catastrophic event, is un-
certain. Previous randomized data indicated
a higher risk of stent thrombosis after 1 year
with DES (1,2), yet more recent studies sug-
gest a lower risk when compared with BMS
(3–5). Whether these ﬁndings are applicable
to a broader range of clinical indications is
unknown.
Although current clinical practice guide-
lines recommend a minimum of only 1
month of dual antiplatelet therapy after BMS
placement following elective PCI (compared
with 6 to 12 months for DES) (6,7), patientswith acute coronary syndromes (ACS) beneﬁt from 12
months of therapy whether or not PCI with stenting
is performed (8). A recent randomized trial (DAPT
[Dual Antiplatelet Therapy]) demonstrated a reduc-
tion in stent thrombosis and non–stent-related
myocardial infarction with thienopyridine therapy
beyond 12 months following DES placement (9),
and consistent ﬁndings among a smaller cohort of
BMS-treated subjects, which included an increase in
bleeding (10). Because BMS remain a commonly
used alternative treatment strategy to DES, parti-
cularly for patients who present with ACS or in
whom dual antiplatelet therapy has a perceived
increased bleeding risk (11,12), we aimed to deter-
mine whether the risks of stent thrombosis and non–
stent-related adverse cardiovascular events differ for
BMS and DES in a powered, prospective, compara-
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STUDY DESIGN. The DAPT study design has previ-
ously been described (13). This double-blind, inter-
national randomized controlled trial (NCT00977938)
compared the risks and beneﬁts of continued thie-
nopyridine (clopidogrel or prasugrel) versus placebo,
when given in addition to aspirin for the prevention
of stent thrombosis or major adverse cardiovascular
and cerebrovascular events (MACCE) following coro-
nary stenting with either DES or BMS. The results
comparing continued thienopyridine versus placebo
(randomized treatment) in each of the DES- and BMS-
treated cohorts have been reported separately (9,10).
Choice of stent type (DES or BMS) was not randomly
assigned, although study inclusion/exclusion criteria
(including lack of contraindication to DAPT therapy)
were similar for both stent types. A prospective sec-
ondary analysis was designed to compare rates
of stent thrombosis and MACCE between DES- and
BMS-treated subjects who were both eligible to
receive DAPT for at least 1 year after the index
procedure.
All institutions received approval from their insti-
tutional review boards, and each subject provided
written informed consent for study participation.
STUDY OBJECTIVES AND HYPOTHESIS. We hypoth-
esized that DES-treated subjects would have stent
thrombosis and MACCE (composite of death,
myocardial infarction, or stroke) rates that were
noninferior to those of BMS-treated subjects through
33 months following the index stent procedure.
STUDY POPULATION AND PROCEDURES. In brief,
subjects who were candidates for dual antiplateletMerck-Sharpe Dohme, Novartis, Pﬁzer, Regeneron,
ax. Dr. Gershlick has received lecture fees and travel
tt Vascular. Dr. Meredith is an international proctor
ry Boards of Boston Scientiﬁc and Medtronic. Dr.
ton Scientiﬁc. Dr. Tanguay has received consultant’s
d Eli Lily and Company. Dr. Windecker has received
c, Edwards Lifesciences, Medtronic, The Medicines
aZeneca, Eli Lilly and Company, Abbott, Biotronik,
ston Scientiﬁc, Daiichi-Sankyo/Lilly, The Medicines
rom Abbott Vascular, CeloNova; and has equity in
Kandzari has received research/grant support from
onoraria from Medtronic and Boston Scientiﬁc. Dr.
r. Simon is on the Advisory Board of Medtronic. Dr.
c, Cordis, Medtronic, Eli Lilly and Company, Daiichi
for Medtronic, Eli Lilly and Company, Boehringer
they have no relationships relevant to the contents
5, accepted May 8, 2015.
FIGURE 1 Subject Flow Diagram
Disposition of subjects in the study. A BMS-treated subject was matched to a variable number of DES-treated subjects without replacement,
up to a maximum of 8. BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s).
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1555therapy and who received treatment with either DES
or BMS were recruited. Stent treatment was per-
formed according to site standards of care using only
Food and Drug Administration–approved DES and
BMS devices. DES types included Cypher sirolimus-
eluting stent (Cordis, Warren, New Jersey), Endeavor
zotarolimus-eluting stent (Medtronic, Santa Rosa,
California), TAXUS paclitaxel-eluting stent (Boston
Scientiﬁc, Marlborough, Massachusetts), and Xience/
Promus everolimus-eluting stents (Abbott Vascular,
Santa Clara, California, or Boston Scientiﬁc). DES-
treated subjects were those who received DES at the
index procedure, regardless of any other type of stent
received at or after the index procedure. BMS-treated
subjects were those treated with BMS only, during the
index procedure or the following 6 weeks. All subjects
signed the consent and were enrolled into the trial
within 3 days of the index procedure, and all received
open-label aspirin plus thienopyridine (either clopi-
dogrel or prasugrel) for the ﬁrst 12 months. At 12
months, subjects who were alive and free from
myocardial infarction, stroke, repeat coronary revas-
cularization, stent thrombosis, and moderate or se-
vere bleeding and who demonstrated compliance with
thienopyridine treatment (deﬁned as having taken
80% to 120% of the drug without an interruption oflonger than 14 days) were then eligible for randomi-
zation to continued thienopyridine or placebo, and all
continued aspirin.
PROPENSITY ANALYSIS COHORT. Because DES use
was more prevalent than BMS use during the time of
enrollment, we employed a propensity-matched
study design for DES–BMS comparisons rather than
randomization to stent type, but required the same
inclusion criteria for DES- and BMS-treated subjects
(13). The propensity analysis cohort included enrolled
subjects (randomized or not). The DAPT study uti-
lized uniform enrollment and randomization criteria,
and central endpoint adjudication, yet allowed
enrollment via 5 contributing studies (13). Although
all randomized subjects were to be followed for 33
months regardless of the study source, in 2 contrib-
uting studies subjects who were not randomized were
not followed beyond 12 months (Xience V USA DAPT
[XIENCE V USA Dual Antiplatelet Therapy (DAPT)
Cohort], NCT01106534; EDUCATE [EDUCATE: The
MEDTRONIC Endeavor Drug Eluting Stenting: Un-
derstanding Care, Antiplatelet Agents and Throm-
botic Events], NCT01069003), and in 3 of the
contributing studies, subjects were consented for
follow-up through 33 months regardless of randomi-
zation status (TAXUS Liberte Post Approval Study,
TABLE 1 Propensity Analysis Cohort Baseline Characteristics
Measure*
Before Match
After Match
(Weighted for match ratio)
DES
(n ¼ 13,257)
BMS
(n ¼ 2,056)
DES
(n ¼ 8,308)
BMS
(n ¼ 1,718)
Standardized
Difference
Clinical characteristics
Age, yrs, mean 61.9 59.8 60.6 60.3 0.035
Female 27.0 25.6 26.4 26.4 0.000
Race, non-white† 10.0 8.1 9.0 8.6 0.014
Hispanic or Latino ethnic group 3.7 5.1 4.8 4.7 0.005
Weight, kg, mean 91.0 88.2 89.5 88.7 0.054
BMI, kg/m2, mean 30.4 29.6 29.8 29.8 0.004
Diabetes mellitus 32.0 23.8 25.8 25.6 0.005
Hypertension 76.3 67.0 69.7 69.6 0.002
Cigarette smoker 25.0 42.2 36.5 38.7 0.045
Stroke/TIA 3.4 4.9 4.4 5.0 0.028
Congestive heart failure 5.6 4.8 5.2 5.0 0.009
Peripheral arterial disease 6.6 6.0 6.5 6.4 0.004
Prior PCI 33.4 20.2 23.2 22.7 0.012
Prior CABG 13.1 7.5 8.3 8.3 0.000
Previous MI 22.6 20.5 21.0 21.6 0.015
Positive stress test 40.3 20.7 28.6 24.2 0.100
Indication for PCI
STEMI 10.5 36.1 27.6 27.6 0.000
NSTEMI 15.1 20.8 20.6 21.9 0.032
Stable angina 37.5 23.5 28.1 27.8 0.007
Unstable angina‡ 18.0 9.8 11.3 11.4 0.003
Other 18.9 9.8 12.4 11.3 0.034
Procedure characteristics
Number of treated lesions
per subject, mean
1.3 1.2 1.2 1.2 0.047
Number of treated vessels
per subject, mean
1.1 1.1 1.1 1.1 0.028
Treated vessel(s)
Native coronary 96.4 96.5 96.4 96.3 0.005
Left main 1.0 0.3 0.8 0.3 0.057
LAD 40.6 30.4 33.2 31.8 0.030
RCA 31.7 45.3 39.2 42.9 0.075
Circumﬂex 23.1 20.6 23.3 21.3 0.048
Venous graft 2.9 3.5 3.1 3.7 0.033
Arterial graft 0.7 0.0 0.6 0.1 0.100
Modiﬁed ACC/AHA lesion
class B2 or C
47.0 50.6 48.7 48.7 0.000
Number of stents per
subject, mean
1.5 1.3 1.4 1.3 0.051
Minimum stent diameter, mm,
per subject
<3 48.9 25.5 30.3 28.9 0.031
3 30.1 32.2 32.0 32.7 0.015
>3 21.0 42.3 37.7 38.5 0.016
Total stent length, mm,
per subject, mean
28.5 23.9 24.6 24.2 0.038
Prasugrel at discharge 38.7 12.8 16.6 15.0 0.044
Clopidogrel at discharge 61.3 87.2 83.4 85.0 0.044
Values are %, except as noted. Characteristics are shown among drug-eluting stent– and bare-metal stent–treated
subjects before and after propensity matching. After match, means, proportions, and standardized differences are
weighted for the variable match ratio. *For most variables, 0% to 3% of subjects had missing values; 23% of patients
weremissing stress test informationdue to thevariable not being collected in one contributing study. †Race and ethnic
group were self-reported. ‡This category included unstable angina without reported elevation of cardiac enzymes.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; BMI ¼ body mass index; BMS ¼
bare-metal stent(s); CABG ¼ coronary artery bypass graft; DES ¼ drug-eluting stent(s); LAD ¼ left anterior
descending coronary artery; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial
infarction; PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary artery; STEMI ¼ ST-segment
elevation myocardial infarction; TIA ¼ transient ischemic attack.
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1556NCT00997503; CYPRESS [CYPHER for Evaluating
Sustained Safety], NCT00954707; The Dual Anti-
platelet Therapy [DAPT] Study, NCT00977938). Sub-
jects enrolled in the latter 3 studies were therefore
considered eligible for propensity-matched analysis
and evaluation of 0- to 33-month data. The present
analysis is restricted to those subjects who reached at
least the 30-month follow-up visit window (30
months  30 days), or those who had experienced a
stent thrombosis or MACCE event before that time, in
order to ensure comparable follow-up duration be-
tween analysis groups.
STUDY ENDPOINTS. The effectiveness endpoints
were cumulative incidence of deﬁnite/probable stent
thrombosis (14) and incidence of MACCE at 0 to 33
months in the propensity-matched DES versus BMS
comparison. These events were adjudicated by an
independent clinical events committee blinded to
treatment assignment and administered by Harvard
Clinical Research Institute. An unblinded indepen-
dent central data monitoring committee oversaw the
safety of all subjects.
STATISTICAL ANALYSIS. Due to the nonrandomized
nature of DES versus BMS comparisons, differences
between DES- and BMS-treated subjects with respect
to distribution of baseline characteristics were ex-
pected (11,12). To account for this, the primary analysis
was conducted on a subsample created by matching
BMS- to DES-treated subjects exactly on prevalence of
ST-segment elevation myocardial infarction (STEMI)
and then matching on remaining baseline character-
istics via propensity score, using a caliper width of
0.10. A BMS-treated subject was matched to a variable
number of DES-treated subjects without replacement,
up to a maximum of 8 (15). The 55 variables used in
propensity scorematching are listed in Online Figure 1.
To assess the adequacy of the match, weighted stan-
dardized differences in clinical characteristics be-
tween groups were calculated, with absolute
differences of <10% considered evidence of balance.
Additional secondary events not expected to differ
between DES after match and BMS were compared to
assess for residual confounding. These included
moderate or severe bleeding (GUSTO [Global Utiliza-
tion of Streptokinase and TPA for Occluded Arteries]
classiﬁcation) (16) at 12 to 30 months, stroke, and non-
stent thrombosis–related myocardial infarction.
BMS and weighted DES event rates were calcu-
lated, where the DES subject weight was the inverse
of the number of DES subjects matched to the same
BMS subject. Noninferiority was assessed via risk
differences (RDs) using the Nam and Kwon (17)
method to account for sample size and for
TABLE 2 Propensity Analysis Cohort Baseline Stent Thrombosis Risk Factors
Measure
Before Match After Match (Weighted for Match Ratio)
DES
(n ¼ 13,257)
BMS
(n ¼ 2,056)
DES
(n ¼ 8,308)
BMS
(n ¼ 1,718)
Standardized
Difference
Any clinical 32.1 62.4 54.8 55.7 0.018
Enzyme-positive ACS (STEMI or NSTEMI) 25.6 56.9 48.2 49.5 0.026
Renal insufﬁciency/failure 4.8 4.0 4.0 3.9 0.005
LVEF <30%* 1.9 4.2 3.5 3.5 0.000
Any lesion-related 33.3 37.9 33.7 33.7 0.000
>2 vessels stented 0.5 0.0 0.1 0.1 0.000
>2 lesions per vessel 2.3 1.2 1.4 1.3 0.009
Lesion length $30 mm* 11.1 6.6 7.0 6.7 0.012
Bifurcation lesion side branch $2.5 mm 6.0 4.4 4.9 4.7 0.009
In-stent restenosis of a DES 4.5 0.8 1.1 0.9 0.020
Vein bypass graft stented 3.4 3.6 3.4 3.8 0.021
Unprotected left main stented 0.6 0.1 0.2 0.2 0.000
Thrombus-containing lesion 10.5 25.6 20.1 20.1 0.000
Prior brachytherapy 0.3 0.1 0.1 0.1 0.000
Any risk factor 51.8 69.3 64.0 63.9 0.002
Values are %. *For most variables, 0% to 3% of subjects had missing values; 6% of patients were missing LVEF.
ACS ¼ acute coronary syndrome; LVEF ¼ left ventricular ejection fraction; other abbreviations as in Table 1.
TABLE 3 Primary Outcomes: Stent Thrombosis and MACCE at 0 to 33 Months Among
Propensity-Matched Subjects Treated With DES or BMS
DES
(n ¼ 8,308)
BMS
(n ¼ 1,718)
Weighted
Risk
Difference
1-Sided
97.5%
Upper CL
1-Sided
p Value
Noninferiority
p Value
for
Difference
Stent thrombosis 1.7 2.6 1.1 0.27 <0.001 0.01
Deﬁnite 1.4 2.5 1.1 0.01
Probable 0.3 0.13 0.1 0.56
MACCE (death,
MI, stroke)
11.4 13.2 1.8 0.03 <0.001 0.053
Death 4.2 5.1 0.8 0.16
Cardiac 2.4 2.9 0.6 0.19
Vascular 0.3 0.3 0.1 0.64
Noncardiovascular 1.6 2.0 0.3 0.39
MI 7.2 8.1 0.8 0.27
Stroke (total) 1.8 2.1 0.2 0.49
Ischemic 1.5 1.6 0.1 0.67
Hemorrhagic 0.4 0.4 0.1 0.75
Uncertain type 0.05 0.3 0.2 0.12
Values are %. Drug-eluting stent outcome rates and risk differences are weighted according to the matched set.
The 1-sided tests of noninferiority on the co-primary endpoints of stent thrombosis and MACCE were based on
noninferiority margins of 0.97% and 2.28%, respectively.
CL ¼ conﬁdence limit; MACCE ¼major adverse cardiac and cerebrovascular events; MI ¼myocardial infarction;
other abbreviations as in Table 1.
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(this RD does not necessarily equal the difference
between BMS and weighted DES event rates). Non-
inferiority margins of 0.97% for stent thrombosis and
2.28% for MACCE were used. After noninferiority was
met, we subsequently conducted a 2-sided test for
difference at the 0.05 signiﬁcance level. As a sec-
ondary analysis, the crude rates of events between
groups and propensity-adjusted noninferiority anal-
ysis were performed on all eligible DES- and BMS-
treated subjects (Online Table 1, Online Methods
Section 2.3).
Also, given recent randomized data indicating
lower rates of stent thrombosis with newer
(everolimus- and zotarolimus-eluting) compared with
older (paclitaxel- and sirolimus-eluting) DES, we
examined the consistency of the stent thrombosis
comparison to BMS by individual DES type (18,19).
Finally, we estimated the effect of a possible un-
measured confounder using a Bayesian probabilistic
approach based on Monte Carlo (Markov Chain Monte
Carlo) sampling (20), and convergence of the Markov
Chain Monte Carlo sampler using the Brooks-Gelman-
Rubin method (21) assuming: 1) independence of the
possible confounder from all measured covariates;
2) an odds ratio on each outcome that could range
from one-third to 3; and 3) with prevalence of
30% versus 70% between the 2 treatment groups. All
analyses presented were pre-speciﬁed except this
sensitivity analysis evaluation of consistency of
treatment effect across DES types (vs. BMS), andcomparison of 12-month outcomes between DES and
BMS.
All statistical analyses were conducted at Harvard
Clinical Research Institute with SAS software,
version 9.2. (SAS Institute, Cary, North Carolina),
and for Markov Chain Monte Carlo sampling, JAGS
Software version 3.4.0. Noninferiority p values are
1-sided and are considered signiﬁcant at the 0.025
FIGURE 2 Propensity-Matched DES and BMS Subjects, 0 to 33 Months Follow-Up
(A) Stent thrombosis and MACCE. (B) Events not related to stent. MACCE ¼ major adverse
cardiovascular and cerebrovascular events; MI ¼myocardial infarction; other abbreviations
as in Figure 1.
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1558level; all other p values are 2-sided and considered
signiﬁcant at the 0.05 level.
RESULTS
STUDY POPULATION. Enrollment in the DAPT study
was conducted between August 2009 and July 2011.
A total of 13,257 DES-treated and 2,056 BMS-treated
subjects were eligible for propensity matching, with
a median follow-up of 990 and 990 days, respectively
(Figure 1). Results comparing only randomized sub-
jects (continued thienopyridine or placebo) have been
reported separately (9,10).
Although the same inclusion and exclusion criteria
were applied to all enrolled subjects, DES- and BMS-
treated subjects differed according to clinical andprocedural characteristics (Table 1). DES-treated sub-
jects were more likely to have a history of diabetes
mellitus, hypertension, previous PCI, and to have
longer lesions, with smaller reference vessel diam-
eter, whereas BMS-treated subjects were more likely
to present with STEMI, or non-STEMI, and have evi-
dence of thrombus in the treated lesion.
PROPENSITY MATCH DES VERSUS BMS COHORT.
Propensity-matched cohorts were similar with
respect to clinical- and lesion-related variables, with
standardized differences within 10% for all match
variables (Table 1, Online Figure 1). Importantly, pre-
speciﬁed risk factors for stent thrombosis were
similar between matched DES- and BMS-treated
subjects with at least 1 risk factor present in 64.0%
and 63.9% respectively (Table 2). Thienopyridine
therapy adherence did not differ between matched
DES and BMS groups (94.5% vs. 94.4%, p ¼ 0.86) at
12 months follow-up. Among subjects in the
propensity-matched sample, 61.4% of DES and 76.0%
of BMS were also randomized.
After matching, DES-treated subjects had an inci-
dence of stent thrombosis over the 0- to 33-month
period that was lower than that of BMS-treated sub-
jects (1.7% vs. 2.6%, weighted RD: 1.1%, 1-sided
upper 97.5% conﬁdence limit 0.27%, noninferiority
p < 0.001, p for difference ¼ 0.01) (Table 3, Figure 2A)
In addition, DES-treated subjects had an incidence of
MACCE that was noninferior to that of BMS-treated
subjects (11.4% vs. 13.2%, weighted RD 1.8%,
1-sided upper 97.5% conﬁdence limit 0.03%, non-
inferiority p < 0.001; p for difference ¼ 0.053). For
both stent thrombosis and MACCE, the major portions
of this RD were observed within the ﬁrst 12 months (0
to 12 months, weighted RD: 1.0%, p for difference ¼
0.002 for stent thrombosis; 1.8% weighted RD, p for
difference ¼ 0.011 for MACCE) (Figure 3). A secondary
analysis using propensity score adjustment was
consistent with the primary analysis (Online Table 1).
Moderate or severe bleeding events were similar
for matched DES and BMS (4.0% vs. 3.7% weighted
RD: 0.5%, p ¼ 0.32) (Figure 2B) as was the incidence of
stroke (1.8% vs. 2.1%, weighted RD: 0.2%, p = 0.49)
(Table 3, Figure 2B), and myocardial infarction not
related to stent thrombosis (6.0% vs. 6.5%, weighted
RD: 0.2%; p ¼ 0.76) (Figure 2B).
Although the RD favoring DES (vs. BMS) for MACCE
was similar for each of the 4 separate DES types, the
RD favoring DES (vs. BMS) for stent thrombosis was
evident for all DES types except the TAXUS
paclitaxel-eluting stent (PES) (Figure 4). In a Bayesian
sensitivity analysis examining the impact of a plau-
sible unmeasured confounder, we found that the
primary conclusions remained robust.
FIGURE 3 Cumulative Incidence of Primary Outcomes in Propensity-Matched DES- or BMS-Treated Subjects
Weighted Kaplan-Meier curves for cumulative incidence of stent thrombosis (A) and MACCE (B), according to drug-eluting vs. bare metal stents
in propensity-matched subjects. ARC ¼ Academic Research Consortium; RD ¼ risk difference; ST ¼ stent thrombosis; other abbreviations as in
Figures 1 and 2.
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We found that propensity-matched BMS-treated sub-
jects had higher rates of stent thrombosis compared
with DES-treated subjects, with the largest portion of
RD accrued during the ﬁrst year after stent treatment.
In addition, rates of MACCE were noninferior among
DES- versus BMS-treated subjects through 33 months
and were signiﬁcantly lower following DES at 1 year.
Previous randomized trials comparing outcomes
following DES or BMS have either utilized older-
generation DES (1,2) or, more recently, been limited
to subjects with acute myocardial infarction (5).Unfortunately, dual antiplatelet therapy duration and
adherence have not been uniform across stent types
in many of these studies. Similarly, in retrospective
observational studies, important variables related to
dual antiplatelet therapy adherence and/or previous
bleeding history are often not included and may
confound comparisons between stent types. In this
regard, the DAPT study was designed to include a
prospective propensity-matched comparison of DES-
and BMS-treated subjects with uniform inclusion
criteria (speciﬁcally requiring subjects to be eligible
for continued thienopyridine therapy), uniform clin-
ical follow-up, and blinded adjudication of endpoints
FIGURE 4 Primary Outcomes by DES Type
Matched weighted risk differences (versus bare-metal stents) over 0- to 33-month time course. Risk differences for stent thrombosis favor DES
except for PES. Risk differences for MACCE favor DES. Abbreviations as in Figures 1 and 2.
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(13). Furthermore, among both DES and BMS
propensity-matched subjects who were randomized,
study medication adherence was identical. Indeed,
the similarities in bleeding events, stroke rates, and
rates of myocardial infarction not related to stent
thrombosis (DES vs. BMS) in the propensity-matched
analysis suggest lack of residual confounding. Lastly,
the analysis of individual DES types with their
matched BMS-treated cohorts provides unique in-
sights into a differential risk of stent thrombosis.
Although DES are often aggregated for purpose of
analysis, a differential risk for stent thrombosis (lack
of RD favoring DES) was evident only for the PES. All
other DES included in analysis had lower rates of
stent thrombosis compared with BMS. Of note, a
higher rate of stent thrombosis has been observed
following PES in pooled patient-level data from ran-
domized comparative trials with BMS and appears
consistent with the present observation (22). Addi-
tionally, the present observation is supported by the
facts that: 1) stent thrombosis rates for the sirolimus-
and PES and BMS included in propensity match
analysis are similar to those reported for similar stent
types in previous randomized trials (1,2); and 2) the
current results are consistent with recent randomized
trial data comparing DES with BMS in subjects with
acute myocardial infarction that demonstrate a
reduction in stent thrombosis risk for newer DES (5).
The observation that all 4 DES types (including PES)have a lower risk for MACCE than their matched BMS
cohorts suggests that stent thrombosis is not the sole
or main driver of MACCE and that restenosis beneﬁt,
common to all 4 DES types (vs. BMS), may be opera-
tive. Indeed, BMS-treated subjects accrue both target
lesion (stent) related events in $2%/year (23) and
non-target lesion/vessel events in $5% per year
following stent deployment (24,25). Athero-
thrombotic events following BMS may be due to lack
of healing/uncovered stent struts, neoatherosclerosis
(26), restenosis (27), or disease progression outside
the stent, in other regions or vessels. The fact that the
major portion of RD between DES and BMS is accrued
early, within 12 months, would be consistent both
with the known differential occurrence of restenosis
between DES and BMS in this time frame as well as
the premise that restenosis may not be benign (27).
Although MACCE is inﬂuenced by events outside of
stent thrombosis, the rates of stent thrombosis and
MACCE were both directionally consistent in favor of
DES. Comparison of DES with BMS did conclude
noninferiority on MACCE as primarily designed, yet
did not reach statistical signiﬁcant difference favor-
ing DES. Nonetheless, the absolute reduction in rates
of MACCE associated with DES compared with BMS
(1.8 percentage point reduction) was similar or
greater in magnitude to that of stent thrombosis (1.1
percentage point reduction). The lack of statistical
signiﬁcance on the MACCE is, therefore, a reﬂection
that only 20% of the MACCE were stent related.
PERSPECTIVES
WHAT IS KNOWN? BMS are a commonly used alternative
treatment strategy to DES, particularly for patients who
present with acute coronary syndrome or in whom dual
antiplatelet therapy has increased bleeding risk. BMS are
perceived to be associated with fewer adverse ischemic
events and to require shorter-duration dual antiplatelet therapy
than DES.
WHAT IS NEW? A prospective, powered, propensity-match
analysis comparing BMS and DES treated patients enrolled
into the DAPT study demonstrated BMS to have increased risk for
stent thrombosis during 0 to 33 months following stent
deployment with the major portion of risk difference (vs. DES)
being present in the ﬁrst 12 months.
WHAT IS NEXT? This study contributes to the growing body of
evidence regarding comparative rates of stent thrombosis and
other adverse ischemic events (BMS vs. DES), which may inform
future guidelines for both stent use as well as duration of dual
antiplatelet therapy.
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would not be expected to differ) between stent types
(e.g., myocardial infarction not related to stent
thrombosis).
STUDY LIMITATIONS. There are several limitations
of this propensity-matched analysis. First, although
propensity score matching was used to overcome
confounding related to measured factors, the po-
tential presence of unrecognized confounders re-
mains a limitation of this nonrandomized analysis.
However, the lack of differences in bleeding (not
expected to differ between stent types), stroke, and
myocardial infarction not related to stent thrombosis
provide reassurance that residual confounding is
limited. Second, although propensity matching is a
preferred method to reduce selection bias, inference
is limited to the population selected for the match.
Although the majority of enrolled BMS-treated sub-
jects were used for the match (84%), a lesser pro-
portion of DES-treated subjects (63%) were selected,
and these appear to represent a group with lower
lesion complexity and diabetes prevalence, but
higher frequency of STEMI indication for revascu-
larization than the overall DAPT study DES-treated
population. Third, although we performed a sensi-
tivity analysis to determine the consistency of the
DES versus BMS comparison, we did not compare
different types of DES to one another, as such
comparisons were not randomized, pre-speciﬁed, or
powered.
CONCLUSIONS
DES were associated with a lower long-term rate of
stent thrombosis and a noninferior rate of MACCE
compared with BMS, among subjects eligible for
treatment with continued thienopyridine and aspirin
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